J. Sirot

5.5k total citations
129 papers, 4.4k citations indexed

About

J. Sirot is a scholar working on Molecular Medicine, Pharmacology and Endocrinology. According to data from OpenAlex, J. Sirot has authored 129 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 77 papers in Molecular Medicine, 40 papers in Pharmacology and 32 papers in Endocrinology. Recurrent topics in J. Sirot's work include Antibiotic Resistance in Bacteria (77 papers), Antibiotics Pharmacokinetics and Efficacy (35 papers) and Bacterial biofilms and quorum sensing (18 papers). J. Sirot is often cited by papers focused on Antibiotic Resistance in Bacteria (77 papers), Antibiotics Pharmacokinetics and Efficacy (35 papers) and Bacterial biofilms and quorum sensing (18 papers). J. Sirot collaborates with scholars based in France, United States and Switzerland. J. Sirot's co-authors include D. Sirot, Roger Labia, C. Chanal, Christophe de Champs, Richard Bonnet, R Cluzel, Christiane Forestier, B Joly, A Petit and A Morand and has published in prestigious journals such as Journal of Molecular Biology, Clinical Infectious Diseases and Journal of Clinical Microbiology.

In The Last Decade

J. Sirot

121 papers receiving 4.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J. Sirot France 39 3.1k 1.6k 1.0k 866 772 129 4.4k
A. Bauernfeind Germany 35 3.0k 1.0× 1.1k 0.7× 1.2k 1.1× 1.3k 1.5× 1.2k 1.6× 148 4.6k
N.J. Legakis Greece 40 2.6k 0.8× 1.1k 0.7× 1.1k 1.0× 754 0.9× 1.5k 1.9× 187 5.1k
Mary E. Kaufmann United Kingdom 26 3.0k 1.0× 1.8k 1.1× 1.2k 1.1× 616 0.7× 689 0.9× 49 4.0k
Naohiro Shibata Japan 30 2.8k 0.9× 1.2k 0.7× 958 0.9× 663 0.8× 795 1.0× 51 3.5k
Christophe de Champs France 38 2.4k 0.8× 1.4k 0.9× 991 0.9× 529 0.6× 885 1.1× 124 4.3k
D. M. Livermore United Kingdom 22 3.7k 1.2× 1.3k 0.8× 1.2k 1.2× 1.2k 1.3× 1.0k 1.3× 25 4.8k
Panayotis T. Tassios Greece 25 2.1k 0.7× 1.0k 0.6× 805 0.8× 554 0.6× 755 1.0× 55 3.8k
Dominique Decré France 33 3.8k 1.2× 1.9k 1.1× 902 0.9× 573 0.7× 1.2k 1.5× 81 4.9k
Ferrán Navarro Spain 41 2.9k 0.9× 1.5k 0.9× 939 0.9× 571 0.7× 1.0k 1.3× 147 4.8k
Marie-Hélène Nicolas-Chanoine France 40 3.3k 1.1× 1.9k 1.2× 850 0.8× 577 0.7× 1.7k 2.2× 91 5.0k

Countries citing papers authored by J. Sirot

Since Specialization
Citations

This map shows the geographic impact of J. Sirot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Sirot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Sirot more than expected).

Fields of papers citing papers by J. Sirot

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Sirot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Sirot. The network helps show where J. Sirot may publish in the future.

Co-authorship network of co-authors of J. Sirot

This figure shows the co-authorship network connecting the top 25 collaborators of J. Sirot. A scholar is included among the top collaborators of J. Sirot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Sirot. J. Sirot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Robin, Frédéric, Julien Delmas, C. Chanal, et al.. (2005). TEM-109 (CMT-5), a Natural Complex Mutant of TEM-1 β-Lactamase Combining the Amino Acid Substitutions of TEM-6 and TEM-33 (IRT-5). Antimicrobial Agents and Chemotherapy. 49(11). 4443–4447. 26 indexed citations
3.
Pradel, Nathalie, Christophe de Champs, J. Sirot, et al.. (2000). Les infections à Escherichia coli producteurs de vérotoxines: étude de la prévalence chez l'enfant dans la région Auvergne. Archives de Pédiatrie. 7. S544–S550. 7 indexed citations
4.
Bonnet, Richard, Jorge Luiz Mello Sampaio, C. Chanal, et al.. (2000). A Novel Class A Extended-Spectrum β-Lactamase (BES-1) in Serratia marcescens Isolated in Brazil. Antimicrobial Agents and Chemotherapy. 44(11). 3061–3068. 82 indexed citations
5.
Souweine, Bertrand, Ousmane Traoré, Bruno Aublet‐Cuvelier, et al.. (1999). Dialysis and central venous catheter infections in critically ill patients: Results of a prospective study. Critical Care Medicine. 27(11). 2394–2398. 42 indexed citations
6.
Sirot, J., Patrice Courvalin, & Claude–James Soussy. (1996). Definition and determination of in vitro antibiotic susceptibility breakpoints for bacteria. Clinical Microbiology and Infection. 2. S5–S10. 21 indexed citations
7.
Thabaut, A, J Avril, Cécile Bébéar, et al.. (1995). Evolution de la sensibilité des bacilles à Gram négatif à la ceftazidime et à trois autres bêta-lactamines en milieu hospitalier de 1989 à 1993. Médecine et Maladies Infectieuses. 25. 6–19. 3 indexed citations
8.
Sirot, D., C. Chanal, Cécile Henquell, et al.. (1994). Clinical isolates of Escherichia coli producing multiple TEM mutants resistant to β-lactamase inhibitors. Journal of Antimicrobial Chemotherapy. 33(6). 1117–1126. 34 indexed citations
9.
Champs, Christophe de, et al.. (1989). Prospective survey of colonization and infection caused by expanded-spectrum-beta-lactamase-producing members of the family Enterobacteriaceae in an intensive care unit. Journal of Clinical Microbiology. 27(12). 2887–2890. 110 indexed citations
10.
Labia, Roger, A Thabaut, A Morand, et al.. (1989). The kinetics of CAZ-5, a novel SHV-related plasmid-mediated beta-lactamase with enhanced hydrolytic activity against ceftazidime.. PubMed. 15(11-12). 535–40. 2 indexed citations
11.
Labia, Roger, Michel Barthélémy, Jean Péduzzi, et al.. (1989). Proprietes des nouvelles beta-lactamases plasmidiques actives sur les cephalosporines de troisieme generation. position dans la classe a des beta-lactamases. Médecine et Maladies Infectieuses. 19. 27–36. 2 indexed citations
12.
Labia, Roger, A Morand, Kiran Tiwari, et al.. (1988). Interactions of New Plasmid-Mediated  -Lactamases with Third-Generation Cephalosporins. Clinical Infectious Diseases. 10(4). 885–891. 48 indexed citations
13.
Labia, Roger, et al.. (1988). Kinetic properties of two plasmid-mediated β-lactamases from Klebsiella pneumoniae with strong activity against third-generation cephalosporins. Journal of Antimicrobial Chemotherapy. 21(3). 301–307. 25 indexed citations
14.
Sirot, D., Roger Labia, A Petit, et al.. (1988). Comparative study of a novel plasmid-mediated beta-lactamase, CAZ-2, and the CTX-1 and CAZ-1 enzymes conferring resistance to broad-spectrum cephalosporins. Antimicrobial Agents and Chemotherapy. 32(11). 1660–1665. 35 indexed citations
15.
Meyer, Alexander, et al.. (1986). [Actinomyces meyeri actinomycosis: a case with thoracic and tibial localization].. PubMed. 137(8). 649–51. 2 indexed citations
16.
Sirot, J., et al.. (1985). Tolérance de la pefloxacine au cours du traitement d'une série d'infections ostéo-articulaires. Trente six cas.. Therapies. 40(5). 1 indexed citations
17.
Boyer, Michael, et al.. (1984). Technique de dosage du céfotaxime et du desacétyl-céfotaxime dans le sérum par chromatographie liquide haute performance.. 32(4). 285–288. 1 indexed citations
18.
Sirot, J., et al.. (1981). [Role of the bacteriology laboratory in the diagnosis and treatment of osteoarthritis].. PubMed. 48(1). 9–16. 1 indexed citations
19.
Sirot, J. & M Cluzel. (1972). The role of Neisseria mucosa in pyo genie meningitis of children.. Ann. Inst. Pasteur. 122(1). 53–61. 2 indexed citations
20.
Sirot, J., et al.. (1964). [THE THIOAMIDE OF ALPHA-PROPYL-ISONICOTINIC ACID (OU 1321 TH) IN TREATMENT OF PULMONARY TUBERCULOSIS].. PubMed. 28. 1261–88. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by A. Bauernfeind Breakdown of academic impact, for papers by N.J. Legakis Breakdown of academic impact, for papers by Mary E. Kaufmann Breakdown of academic impact, for papers by Naohiro Shibata Breakdown of academic impact, for papers by Christophe de Champs Breakdown of academic impact, for papers by D. M. Livermore Breakdown of academic impact, for papers by Panayotis T. Tassios Breakdown of academic impact, for papers by Dominique Decré Breakdown of academic impact, for papers by Ferrán Navarro Breakdown of academic impact, for papers by Marie-Hélène Nicolas-Chanoine
Rankless by CCL
2026